In this deep-dive episode, we unpack FDA ADHD Stimulant Label Change: Weight Loss Risk PMHNPs Must Know. The FDA now requires all extended-release ADHD stimulants to carry a Limitation of Use warning about weight loss risk in children under 6. Younger kids get higher plasma exposures from ER formulations, leading to clinically significant weight loss (10%+ drop in CDC weight percentile). PMHNPs need a structured monitoring protocol: baseline weight, monthly checks for 3 months, quarterly thereafter, and a 10% percentile drop as the intervention threshold. Immediate-release formulations are not included in this label change and may be preferable for very young patients. Read the full post: https://psychnpfellowship.com/fda-adhd-stimulant-label-change-weight-loss-pmhnp/